Agostino Cortelezzi

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

Renato Bassan, Orietta Spinelli, Elena Oldani et al. · Blood · 2009 · 429 citations · Full text

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

Uwe Platzbecker, Giuseppe Avvisati, Laura Cicconi et al. · Journal of Clinical Oncology · 2016 · 375 citations · Full text

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients

Wilma Barcellini, Bruno Fattizzo, Anna Zaninoni et al. · Blood · 2014 · 359 citations · Full text

Angiogenesis in myelodysplastic syndromes

Giancarlo Pruneri, Francesco Bertolini, Davide Soligo et al. · British Journal of Cancer · 1999 · 271 citations · Full text

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani et al. · Leukemia · 2018 · 233 citations · Full text